Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Payables (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Payables for 6 consecutive years, with $620528.0 as the latest value for Q3 2025.

  • On a quarterly basis, Payables fell 75.47% to $620528.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $620528.0, a 75.47% decrease, with the full-year FY2024 number at $943019.0, up 45.81% from a year prior.
  • Payables was $620528.0 for Q3 2025 at Inhibikase Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.4 million in Q2 2024 to a low of $620528.0 in Q3 2025.
  • A 5-year average of $1.5 million and a median of $1.2 million in 2022 define the central range for Payables.
  • Peak YoY movement for Payables: surged 347.53% in 2024, then plummeted 75.47% in 2025.
  • Inhibikase Therapeutics' Payables stood at $1.3 million in 2021, then decreased by 14.01% to $1.2 million in 2022, then crashed by 43.82% to $646767.0 in 2023, then soared by 45.81% to $943019.0 in 2024, then crashed by 34.2% to $620528.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Payables are $620528.0 (Q3 2025), $2.7 million (Q2 2025), and $1.7 million (Q1 2025).